| GPRO 1.23 40.38% | PCG 14.06 5.95% | LIDR 1.47 27.83% | NVDA 217.44 -1.51% | TSLL 9.33 -6.42% | HKPD 0.1815 -45.54% | NVD 4.05 3.05% | RITR 0.0882 -4.13% | NIO 4.055 -4.14% | FLYE 2.17 59.56% | INTC 88.97 -0.60% | ONDS 7.04 -8.05% | NU 14.46 -0.62% | BITO 10.38 -2.35% | RZLV 2.39 -17.30% | PATH 18.14 -2.84% | AAL 12.95 -3.57% | SOXL 105.91 -6.10% | NOK 9.93 -2.07% | TQQQ 69.15 -3.85% | SPCX 142.23 -1.02% | AAPL 325.13 2.61% | IBIT 43.76 -2.04% | F 13.83 -0.79% | HYG 79.1 -0.89% | SQQQ 39.97 3.79% | PLUG 2.09 -3.24% | SOXS 52.22 6.53% | BIAF 6.59 44.52% | BTG 5.2 -5.11% | SGOV 100.41 -0.28% | CDE 20.2 -2.79% | QID 14.59 2.53% | SOFI 17.05 -4.64% | PFE 28.55 0.32% | BMNR 23.37 -7.70% | GRAB 3.46 -2.26% | SPY 761.74 -0.69% | AIM 0.2406 6.46% | RIG 5.92 1.89% | TSLA 356.09 -3.22% | FRVO 19.75 28.41% | LQD 105.22 -0.93% | QQQ 707.64 -1.27% | IREN 36.82 -0.79% | ETHA 18.23 -2.62% | XLE 64.77 1.27% | SSM 4.755 77.43% | T 26.015 0.48% | XLF 57.2 -0.88%

Danaher Shares Surge 8% After Earnings Beat, Though Full-Year Outlook Slightly Trails Forecasts

Danaher Corporation (NYSE: DHR) shares jumped about 8% in intra-day trading on Tuesday after the life sciences company reported third-quarter results that surpassed analyst expectations, although its full-year earnings guidance landed marginally below consensus at the midpoint.

The company posted earnings per share of $1.89, beating the analyst estimate of $1.72. Revenue rose to $6.05 billion, slightly ahead of the $6 billion consensus forecast.

For fiscal 2025, Danaher projected earnings per share in the range of $7.70 to $7.80, with the midpoint of $7.75 just under the $7.78 analyst consensus. Management said it expects non-GAAP core revenue growth to remain in the low single digits year-over-year.

Executives added that continued progress in bioprocessing and diagnostics, along with operational discipline, supported the quarter’s strong results.

Published on: October 21, 2025